The week in pharma: action, reaction and insight – week to October 20, 2023
By Barbara Obstoj-Cardwell. Editor
Featuring in last week’s news, Swiss firm MoonLake Immunotherapies announced new Phase II MIRA study data showing that its antibody sonelokimab further improved response rate in hidradenitis suppurativa. Last Tuesday, Monte Rosa Therapeutics announced a potentially $2 billion licensing deal with Roche for its molecular glue degrader-based medicine, and also released early-stage results for its cancer candidate MRT-2359. Japan’s Daiichi Sankyo signed a mega bucks deal with US pharma giant Merck & Co for three antibody drug conjugates (ADCs) that could potentially be worth $22 billion. On the M&A front, Eli Lilly agreed to acquire French pre-clinical stage biotech Mablink Biosciences and its lead candidate MBK-103 for an undisclosed amount.
MoonLake’s MIRA 24 week data beats expectations
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze